New Research Report by Researchstore.biz on “Global Immunotherapy Drugs Market By Type of Drugs (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Other), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, Other), End-User (Hospitals, Clinics, Other), Region (North America, Europe, Asia Pacific, South America and Middle East and Africa)” and Global Forecast 2018-2025, presents the worldwide Immunotherapy Drugs Market market size.
The global immunotherapy drugs market was valued at USD 132.59 Billion in 2017 and is projected to reach USD 385.46 Billion by 2025 growing at a CAGR of 14.27% during the forecast period from 2018-2025. Major drivers that fuel the growth of immunotherapy drugs market are:
- Increasing adoption of targeted therapy over traditional therapy
- Emergence of biosimilars
- Rising demand for monoclonal antibodies(MABs)
- A high prevalence rate of lifestyle diseases
- Fast track and orphan drug designations
Immunotherapy drugs improve and smooths the insusceptible arrangement of the human body. Generally used in cancer treatment, these drugs help the generation of antibodies. They work by enabling the resistant arrangement of the body and creating an insusceptible reaction. The antibiotics are used in cancer treatment to kill the dangerous tumor cells. The cases of the prevalence of cancer and various immune system diseases are growing at a rapid pace across the world. Therefore, the demand for immunotherapy drugs, also known as activation immunotherapies, has increased. The immune effector cells including macrophages, cytotoxic T lymphocytes (CTL), dendritic cells, lymphocytes, natural killer cells (NK Cell), etc., collaboratively work to protect the body against cancer. The immune effector cells articulate abnormal antigens on the facade of the cancer cells.
DOWNLOAD FREE SAMPLE REPORT:https://researchstore.biz/report/global-immunotherapy-drugs-market/71586/#requestforsample
Fast track, orphan drug designations and high prevalence rate of lifestyle diseases are projected to drive the Immunotherapy Drugs market:
The immunotherapy drugs market is driven by following key factors:
Increasing adoption of targeted therapy over traditional therapy
The emergence of biosimilars
High prevalence rate of lifestyle diseases
Increasing demand for monoclonal antibodies (MABs) will be the future driving factor for the market.
The market growth limiting factors are:
The high cost of immunotherapy treatment
A high attrition rate in the product development cycle
However, fast track and orphan drug designations would enhance the immunotherapy drugs market over the forecast period.
The global immunotherapy drugs market is segmented on the basis of the end user, type of drugs, therapy area, and regions.
Checkpoint inhibitors segment is expected to reach market share 24.18% during 2018 to 2025
On the basis of type of drugs this market primarily split into: monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and other. The type segment is projected to to extend with the highest CAGR over the forecast period. The cancer treatment leading to growing demand for immunotherapy drugs drives the demand of checkpoint inhibitors segment.
ACCESS FULL REPORT:https://researchstore.biz/report/global-immunotherapy-drugs-market/71586/
Hospitals segment carried the largest market share of 36.78% in 2017
On the basis of the end users/applications, the market covers hospitals, clinics, and other. Further sub-segments covered by market includes home healthcare centres and nursing home facilities. The hospitals’ segment is expected to grow at the highest CAGR over the forecast period. The market share has increased due to the increasing number of hospitals providing quick availability of immunotherapy drugs.
Regional Segmentation Analysis:
The Major segments included in the market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa. In 2017, North America held the largest market share of nearly 28.61%. Rising demand for convenience, low cost of manufacturing and acceptable regulatory scenario led to the growth of immunotherapy drugs market in the mentioned region.
Market competition by top players covers following key players: F.
Hoffmann-La Roche, Merck, AbbVie, AstraZeneca, Johnson & Johnson,
Bristol-Myers Squibb, Coherus BioSciences, ADC Therapeutics,
ChemoCentryx, Boehringer Ingelheim, Argos Therapeutics, Agenus, CTI
BioPharma, AVAX Technologies, Agensys, Biothera, Biogen, Alder
Biopharmaceuticals, Aduro Biotech, Acorda Therapeutics, Eli Lilly,
Amgen, Advaxis, and Bavarian Nordic.
Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (email@example.com), who will ensure that you get a report that suits your needs.